Abstract
Clozapine prescribing in treatment‐refractory schizophrenia is underutilised, including in early intervention for psychosis services. COVID‐19 has brought various challenges to the utilisation of clozapine, particularly in the context of initiation and monitoring. There is a need for clear national guidance in this regard.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
